Transworld Health podcast

Special ESMO 2026 - EN

0:00
10:41
Retroceder 15 segundos
Avanzar 15 segundos
The purpose of this podcast is to provide continuing medical education and inform Healthcare Professionals. This information includes scientific content intended exclusively for Healthcare Professionals authorized to prescribe or dispense medicines or medical devices in Spain, as specialized training is required for its correct interpretation. Access to this content implies confirmation of Healthcare Professional status. Participants express their own opinions, experiences, and conclusions. ----- What new developments has ESMO 2026 brought to the management of biliopancreatic tumours? In this new episode of TooMore GI, Dr. Ángela Lamarca, medical oncologist at Hospital Universitario Fundación Jiménez Díaz, analyses five of the most relevant studies presented at ESMO 2026 and reflects on their impact on the present and future treatment of these tumours. In biliary tract tumours, she analyses the results of the ACTICCA-1 trial, which did not demonstrate a significant improvement in recurrence-free survival (RFS) with gemcitabine/cisplatin compared with capecitabine, with the latter remaining the standard adjuvant treatment. Meanwhile, HARMONi-GI1 has shown an overall survival benefit (HR 0.75), although the results will need to be confirmed in Western populations, as the study was conducted exclusively in China, where there was a high prevalence of hepatitis B. Finally, COMPANION-002 has demonstrated improvements in response rate and progression-free survival (PFS) with tovecimig plus paclitaxel. Two studies that have renewed interest in antiangiogenesis as a therapeutic strategy in advanced disease. Could these advances open new treatment opportunities? In pancreatic cancer, we review the new analyses from the RASolute 302 trial, focusing on the efficacy of daraxonrasib across different KRAS molecular subgroups, as well as the promising preliminary results of INCB161734 in combination with chemotherapy. Two studies that highlight the growing importance of KRAS-targeted therapies and the need to facilitate patient access to clinical trials. An overview of the main scientific advances, the questions that remain unanswered, and future therapeutic opportunities in two particularly complex areas. 🎧 Don't miss this new episode and discover the key insights from ESMO 2026 in biliopancreatic tumours! ---- 3rd Ed. TooMore Gi is also available on: transworldeditors.com/toomore-gi-3/

Otros episodios de "Transworld Health"